Actively Recruiting
Phase 1 Randomized, Double-Blind Study Evaluating Safety and Effects of ALN-6222 in Adults with Obesity
Led by Alnylam Pharmaceuticals · Updated on 2026-10-21
88
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1, randomized, double-blind, placebo-controlled study to evaluate ALN-6222 in adults with obesity. The study focuses on assessing the safety, tolerability, how the drug moves and acts in the body, and its potential effects in participants with a body mass index between 30 and less than 40 kgm. This trial aims to gather important information about ALN-6222 as a treatment option for obesity. Participants will receive a single subcutaneous dose of either ALN-6222 or a placebo. The study uses a parallel design where participants are randomly assigned to one of these two groups. This single ascending dose study will monitor participants over time to observe how the drug behaves and its effects compared to placebo. During the study, participants will be monitored for adverse events for up to 12 months. Researchers will collect blood samples before dosing and up to three days after to measure drug levels and protein markers. Additional assessments of protein markers will continue for up to 12 months after dosing. This comprehensive monitoring helps evaluate the safety and biological impact of ALN-6222 throughout the study period.
CONDITIONS
Brief Title
A Study to Evaluate ALN-6222 in Participants With Obesity
Research Team
A
Alnylam Clinical Trial Information Line
A
Alnylam Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here